리서치사:Market Glass, Inc. (Formerly Global Industry Analysts, Inc.)
발행일:2024년 09월
페이지 정보:영문 367 Pages
라이선스 & 가격 (부가세 별도)
한글목차
골암 치료 세계 시장은 2030년까지 15억 달러에 달할 것으로 전망
2023년 12억 달러로 추정되는 골암 치료 세계 시장은 2030년에는 15억 달러에 달할 것으로 예상되며, 2023-2030년 분석 기간 동안 3.0%의 CAGR로 성장할 것으로 예상됩니다. 본 보고서에서 분석한 부문 중 하나인 골육종 치료는 CAGR 3.4%를 기록하여 분석 기간 종료 시점에 8억 8,040만 달러에 도달할 것으로 예상됩니다. 연골육종 치료 분야의 성장률은 분석 기간 동안 CAGR 2.7%로 추정됩니다.
미국 시장 3억 2,620만 달러로 추정, 중국은 CAGR 5.8%로 성장 전망
미국의 골암 치료 시장은 2023년 3억 2,620만 달러로 추정됩니다. 세계 2위의 경제 대국인 중국은 2023년부터 2030년까지 연평균 5.8%의 성장률을 보이며 2030년에는 2억 9,930만 달러의 시장 규모에 도달할 것으로 예상됩니다. 다른 주목할 만한 지역 시장으로는 일본과 캐나다가 있으며, 분석 기간 동안 각각 0.9%와 2.2%의 CAGR을 기록할 것으로 예상됩니다. 유럽에서는 독일이 연평균 1.5%의 성장률을 보일 것으로 예상됩니다.
세계 골암 치료제 시장 - 주요 동향 및 촉진요인 요약
골암 치료는 어떻게 발전해 왔을까?
골암 치료는 초보적인 접근법에서 고도로 전문화된 표적 치료로 수년 동안 눈부신 발전을 이루었습니다. 전통적으로 골암 치료는 외과적 개입에 크게 의존해 왔으며, 종양을 제거하기 위해 절단이나 사지 보존 수술이 수반되는 경우가 많았습니다. 수술은 여전히 치료의 핵심이지만, 화학요법과 방사선 치료의 도입으로 상황이 크게 바뀌었습니다. 빠르게 분열하는 세포를 표적으로 삼는 화학요법은 수술의 표준 보조요법이 되어 절제 전 종양을 축소하고 수술 후 남아있는 암세포를 제거하는 데 도움이 됩니다. 한편, 방사선 치료는 강도변조방사선치료(IMRT), 양성자치료 등 주변 건강한 조직을 보존하면서 암세포를 표적으로 파괴할 수 있는 보다 정밀한 기술의 등장으로 발전해 왔습니다. 이러한 발전은 생존율을 향상시켰을 뿐만 아니라 환자의 삶의 질을 크게 향상시켰으며, 과감한 수술의 필요성을 줄이고 장기적인 부작용을 최소화하는 데 기여하고 있습니다.
골암 치료의 새로운 트렌드는?
골암 치료의 새로운 트렌드는 보다 개인화된 최소침습적 치료 옵션에 대한 탐색을 통해 이루어지고 있습니다. 가장 중요한 트렌드 중 하나는 암 성장을 촉진하는 특정 유전자 돌연변이 또는 단백질에 초점을 맞춘 표적 치료의 부상입니다. 티로신 키나아제 억제제 및 단클론항체와 같은 약물이 이러한 추세의 최전선에 있으며, 기존 화학요법에 대한 보다 효과적이고 독성이 적은 치료법을 제공하고 있습니다. 또 다른 중요한 트렌드는 면역치료의 발전입니다. 이는 신체의 면역 체계를 이용하여 암과 싸우는 것입니다. 체크포인트 억제제와 CAR T 세포 요법이 이 분야를 선도하고 있으며, 가장 공격적인 골암 치료에도 유망한 치료법으로 떠오르고 있습니다. 또한, PET 스캔과 MRI와 같은 영상 진단의 발전으로 종양의 발견과 모니터링의 정확도가 향상되어 조기 개입과 보다 정확한 치료 계획이 가능해졌습니다. 영상 진단과 치료계획에 인공지능(AI)의 통합도 확산되고 있으며, 이는 종양 전문의에게 치료 결과를 보다 정확하게 예측하고 치료를 맞춤화할 수 있는 도구를 제공하고 있습니다. 또한, 고주파 소작술이나 냉동 절제술과 같은 최소침습 수술 기술의 발전은 특히 기존 수술이 불가능한 환자들에게 새로운 치료 옵션을 제공하고 있습니다.
의료 과학의 혁신은 어떻게 골암 치료를 변화시키고 있는가?
의료 과학의 혁신은 보다 효과적이고 덜 침습적이며 환자 개개인에 맞는 새로운 치료법을 도입하여 골암 치료를 변화시키고 있습니다. 가장 획기적인 기술 혁신 중 하나는 유전자 치료의 개발입니다. 유전자 치료는 암세포의 유전 물질을 변화시켜 암세포의 증식을 막거나 다른 치료법에 대한 민감도를 높이는 것입니다. 현재 임상시험에서 다양한 유전자 치료 접근법이 검토되고 있으며, 일부는 골암 환자의 예후를 개선하는 데 있어 초기부터 유망한 것으로 평가되고 있습니다. 나노기술도 획기적인 연구 분야로, 나노입자를 이용해 종양 부위에 직접 약물을 전달함으로써 건강한 조직 손상을 최소화하고 화학요법의 효과를 높이는데 기여하고 있습니다. 3D 프린팅 기술로 맞춤형 뼈 임플란트 및 보철물을 제작하는 3D 프린팅 기술은 수술 후 회복에 혁명을 일으키고 있으며, 보다 정밀한 재건과 더 나은 기능적 결과를 가능하게 하고 있습니다. 또한, 줄기세포 치료의 발전은 암과 그 치료로 인한 뼈 손상을 복구할 수 있는 가능성을 검토하고 있어 회복과 삶의 질 향상에 대한 희망을 가져다주고 있습니다. 이러한 기술 혁신은 환자가 이용할 수 있는 치료 옵션을 넓힐 뿐만 아니라, 골암을 보다 효과적으로 관리하고 부작용을 최소화할 수 있는 미래를 위한 발판을 마련하고 있습니다.
골암 치료 시장의 성장을 촉진하는 요인은 무엇인가?
골암 치료 시장의 성장은 몇 가지 요인에 의해 주도되고 있으며, 이는 첨단적이고 효과적인 치료법에 대한 수요 증가를 강조하고 있습니다. 첫째, 특히 고령화 사회에서 골암 발생률의 증가가 큰 원동력이 되고 있습니다. 평균 수명이 늘어남에 따라 다양한 유형의 골암을 포함한 노인성 암의 유병률도 증가합니다. 둘째, 의료기술과 제약연구의 지속적인 발전으로 새로운 화학요법제부터 최첨단 면역요법 및 표적치료제까지 사용 가능한 치료법이 확대되고 있습니다. 이러한 기술 혁신은 환자의 예후를 개선하고 새로운 치료법의 보급으로 이어지고 있습니다. 또 다른 중요한 요인은 환자 개개인의 유전자 프로파일에 따라 치료법을 맞춤화하는 맞춤의료의 중요성이 강조되고 있다는 점입니다. 이러한 접근법은 특히 아형에 따라 다양한 치료에 대한 반응이 다른 골암과 관련이 있습니다. 또한, 신흥 시장에서의 의료 인프라 확대와 첨단 의료에 대한 접근성 향상으로 더 많은 환자들이 최첨단 치료법을 이용할 수 있게 되면서 시장 성장에 기여하고 있습니다. 임상시험의 가용성 증가와 암 연구 분야의 세계 공동연구가 활발해짐에 따라 이전에는 이용할 수 없었던 실험적 치료법을 환자들이 이용할 수 있게 된 것도 시장 성장에 박차를 가하고 있습니다. 마지막으로 골암에 대한 인식이 높아지고 조기 발견이 가능해지면서 효과적인 치료와 생존율 향상에 필수적인 조기 개입이 가능해졌고, 이는 고급 치료 옵션에 대한 수요를 촉진하고 있습니다.
조사 대상 기업 예시(34개사)
Atlanthera
Bayer AG
Cadila Pharmaceuticals
CancerVax
Cellectar Biosciences, Inc.
Cipla, Inc.
Debiopharm Group
GlaxoSmithKline plc.
Healthcare Global Enterprises Ltd.
Isofol Medical AB
Janssen Global Services LLC
Johnson and Johnson
Max Healthcare
Novartis International AG
Pfizer Inc.
Zentalis Pharmaceuticals
목차
제1장 조사 방법
제2장 주요 요약
시장 개요
주요 기업
시장 동향과 성장 촉진요인
세계 시장 전망
제3장 시장 분석
미국
캐나다
일본
중국
유럽
프랑스
독일
이탈리아
영국
스페인
러시아
기타 유럽
아시아태평양
호주
인도
한국
기타 아시아태평양
라틴아메리카
아르헨티나
브라질
멕시코
기타 라틴아메리카
중동
이란
이스라엘
사우디아라비아
아랍에미리트
기타 중동
아프리카
제4장 경쟁
ksm
영문 목차
영문목차
Global Bone Cancer Treatment Market to Reach US$1.5 Billion by 2030
The global market for Bone Cancer Treatment estimated at US$1.2 Billion in the year 2023, is expected to reach US$1.5 Billion by 2030, growing at a CAGR of 3.0% over the analysis period 2023-2030. Osteosarcoma Treatment, one of the segments analyzed in the report, is expected to record a 3.4% CAGR and reach US$880.4 Million by the end of the analysis period. Growth in the Chondrosarcoma Treatment segment is estimated at 2.7% CAGR over the analysis period.
The U.S. Market is Estimated at US$326.2 Million While China is Forecast to Grow at 5.8% CAGR
The Bone Cancer Treatment market in the U.S. is estimated at US$326.2 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$299.3 Million by the year 2030 trailing a CAGR of 5.8% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 0.9% and 2.2% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.5% CAGR.
Global Bone Cancer Treatment Market - Key Trends and Drivers Summarized
How Has Bone Cancer Treatment Advanced Over the Years?
Bone cancer treatment has seen remarkable advancements over the years, moving from rudimentary approaches to highly specialized and targeted therapies. Traditionally, treatment for bone cancer relied heavily on surgical intervention, often involving amputation or limb-sparing surgeries to remove the tumor. While surgery remains a cornerstone of treatment, the landscape has shifted dramatically with the introduction of chemotherapy and radiation therapy. Chemotherapy, which targets rapidly dividing cells, became a standard adjunct to surgery, helping to shrink tumors before removal and to eliminate residual cancer cells post-surgery. Radiation therapy, on the other hand, has evolved with the advent of more precise techniques, such as intensity-modulated radiation therapy (IMRT) and proton therapy, which allow for the targeted destruction of cancer cells while sparing surrounding healthy tissue. These developments have not only improved survival rates but have also significantly enhanced the quality of life for patients, reducing the need for drastic surgical procedures and minimizing long-term side effects.
What Are the Emerging Trends in Bone Cancer Treatment?
Emerging trends in bone cancer treatment are driven by the quest for more personalized and less invasive therapeutic options. One of the most significant trends is the rise of targeted therapies, which focus on specific genetic mutations or proteins that drive cancer growth. Drugs like tyrosine kinase inhibitors and monoclonal antibodies are at the forefront of this trend, offering more effective and less toxic alternatives to traditional chemotherapy. Another critical trend is the development of immunotherapy, which harnesses the body’s immune system to fight cancer. Checkpoint inhibitors and CAR T-cell therapy are leading the charge in this area, showing promise in treating even the most aggressive forms of bone cancer. Additionally, advances in diagnostic imaging, such as PET scans and MRI, are improving the accuracy of tumor detection and monitoring, allowing for earlier intervention and more precise treatment planning. The integration of artificial intelligence (AI) in imaging and treatment planning is also gaining traction, providing oncologists with tools to better predict treatment outcomes and personalize therapy. Moreover, the trend towards minimally invasive surgical techniques, such as radiofrequency ablation and cryoablation, is offering new options for patients, particularly those for whom traditional surgery is not viable.
How Are Innovations in Medical Science Transforming Bone Cancer Treatment?
Innovations in medical science are transforming bone cancer treatment by introducing new modalities that are more effective, less invasive, and tailored to the individual patient. One of the most transformative innovations is the development of gene therapy, which involves altering the genetic material within cancer cells to stop their growth or to make them more susceptible to other treatments. Clinical trials are currently exploring various gene therapy approaches, with some showing early promise in improving outcomes for patients with bone cancer. Nanotechnology is another groundbreaking area of research, where nanoparticles are used to deliver drugs directly to the tumor site, minimizing damage to healthy tissue and enhancing the efficacy of chemotherapy. The use of 3D printing technology in the creation of custom bone implants and prosthetics is also revolutionizing post-surgical recovery, allowing for more precise reconstructions and better functional outcomes. Additionally, advances in stem cell therapy are being explored for their potential to repair bone damage caused by cancer or its treatment, offering hope for improved recovery and quality of life. These innovations are not only expanding the treatment options available to patients but are also setting the stage for a future where bone cancer can be managed more effectively and with fewer side effects.
What Factors Are Driving the Growth in the Bone Cancer Treatment Market?
The growth in the bone cancer treatment market is driven by several factors that highlight the increasing demand for advanced and effective therapies. Firstly, the rising incidence of bone cancer, particularly among the aging population, is a significant driver. As life expectancy increases, so does the prevalence of cancers that are more common in older adults, including various types of bone cancer. Secondly, the ongoing advancements in medical technology and pharmaceutical research are expanding the arsenal of available treatments, from novel chemotherapy agents to cutting-edge immunotherapies and targeted therapies. These innovations are improving patient outcomes, leading to greater adoption of new treatment modalities. Another critical factor is the growing emphasis on personalized medicine, where treatments are tailored to the genetic profile of the individual patient. This approach is particularly relevant in bone cancer, where different subtypes respond differently to various treatments. Additionally, the expansion of healthcare infrastructure and access to advanced medical care in emerging markets is contributing to market growth, as more patients gain access to state-of-the-art treatments. The increasing availability of clinical trials and the rise of global collaboration in cancer research are also fueling market expansion, offering patients access to experimental therapies that were previously unavailable. Lastly, the heightened awareness and early detection of bone cancer are leading to earlier intervention, which is crucial for effective treatment and improving survival rates, thereby driving the demand for advanced treatment options.
Select Competitors (Total 34 Featured) -
Atlanthera
Bayer AG
Cadila Pharmaceuticals
CancerVax
Cellectar Biosciences, Inc.
Cipla, Inc.
Debiopharm Group
GlaxoSmithKline plc.
Healthcare Global Enterprises Ltd.
Isofol Medical AB
Janssen Global Services LLC
Johnson and Johnson
Max Healthcare
Novartis International AG
Pfizer Inc.
Zentalis Pharmaceuticals
TABLE OF CONTENTS
I. METHODOLOGY
II. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
Influencer Market Insights
Global Economic Update
Bone Cancer Treatment - Global Key Competitors Percentage Market Share in 2024 (E)
Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
Advancements in Targeted Therapies Propel Growth in Bone Cancer Treatment Market
Rising Incidence of Osteosarcoma Expands Addressable Market Opportunity for Specialized Treatments
Emergence of Immunotherapy Strengthens Business Case for Innovative Bone Cancer Treatments
Advent of Novel Chemotherapy Agents Drive Adoption in Bone Cancer Care
Focus on Precision Medicine Generates Demand for Personalized Bone Cancer Treatment Solutions
Integration of Genomic Testing in Oncology Throws the Spotlight on Tailored Bone Cancer Therapies
Increasing Use of Combination Therapies Spurs Growth in Multi-Modal Bone Cancer Treatment Approaches
Challenges in Early Diagnosis of Bone Cancer Present Opportunities for Advanced Diagnostic Tools
Rising Healthcare Expenditure and Access to Advanced Oncology Care Sustain Growth in Bone Cancer Treatment Market
4. GLOBAL MARKET PERSPECTIVE
TABLE 1: World Bone Cancer Treatment Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
TABLE 2: World Recent Past, Current & Future Analysis for Bone Cancer Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 3: World Historic Review for Bone Cancer Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 4: World 16-Year Perspective for Bone Cancer Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
TABLE 5: World Recent Past, Current & Future Analysis for Osteosarcoma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 6: World Historic Review for Osteosarcoma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 7: World 16-Year Perspective for Osteosarcoma by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 8: World Recent Past, Current & Future Analysis for Chondrosarcoma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 9: World Historic Review for Chondrosarcoma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 10: World 16-Year Perspective for Chondrosarcoma by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 11: World Recent Past, Current & Future Analysis for Ewing Sarcoma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 12: World Historic Review for Ewing Sarcoma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 13: World 16-Year Perspective for Ewing Sarcoma by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 14: World Recent Past, Current & Future Analysis for Other Indications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 15: World Historic Review for Other Indications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 16: World 16-Year Perspective for Other Indications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 17: World Recent Past, Current & Future Analysis for Immunotherapy & Targeted Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 18: World Historic Review for Immunotherapy & Targeted Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 19: World 16-Year Perspective for Immunotherapy & Targeted Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 20: World Recent Past, Current & Future Analysis for Chemotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 21: World Historic Review for Chemotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 22: World 16-Year Perspective for Chemotherapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 23: World Recent Past, Current & Future Analysis for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 24: World Historic Review for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 25: World 16-Year Perspective for Retail Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 26: World Recent Past, Current & Future Analysis for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 27: World Historic Review for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 28: World 16-Year Perspective for Hospital Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 29: World Recent Past, Current & Future Analysis for Online Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 30: World Historic Review for Online Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 31: World 16-Year Perspective for Online Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
III. MARKET ANALYSIS
UNITED STATES
Bone Cancer Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
TABLE 32: USA Recent Past, Current & Future Analysis for Bone Cancer Treatment by Indication - Osteosarcoma, Chondrosarcoma, Ewing Sarcoma and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 33: USA Historic Review for Bone Cancer Treatment by Indication - Osteosarcoma, Chondrosarcoma, Ewing Sarcoma and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 34: USA 16-Year Perspective for Bone Cancer Treatment by Indication - Percentage Breakdown of Value Sales for Osteosarcoma, Chondrosarcoma, Ewing Sarcoma and Other Indications for the Years 2014, 2024 & 2030
TABLE 35: USA Recent Past, Current & Future Analysis for Bone Cancer Treatment by Therapy Type - Immunotherapy & Targeted Therapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 36: USA Historic Review for Bone Cancer Treatment by Therapy Type - Immunotherapy & Targeted Therapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 37: USA 16-Year Perspective for Bone Cancer Treatment by Therapy Type - Percentage Breakdown of Value Sales for Immunotherapy & Targeted Therapy and Chemotherapy for the Years 2014, 2024 & 2030
TABLE 38: USA Recent Past, Current & Future Analysis for Bone Cancer Treatment by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 39: USA Historic Review for Bone Cancer Treatment by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 40: USA 16-Year Perspective for Bone Cancer Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
CANADA
TABLE 41: Canada Recent Past, Current & Future Analysis for Bone Cancer Treatment by Indication - Osteosarcoma, Chondrosarcoma, Ewing Sarcoma and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 42: Canada Historic Review for Bone Cancer Treatment by Indication - Osteosarcoma, Chondrosarcoma, Ewing Sarcoma and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 43: Canada 16-Year Perspective for Bone Cancer Treatment by Indication - Percentage Breakdown of Value Sales for Osteosarcoma, Chondrosarcoma, Ewing Sarcoma and Other Indications for the Years 2014, 2024 & 2030
TABLE 44: Canada Recent Past, Current & Future Analysis for Bone Cancer Treatment by Therapy Type - Immunotherapy & Targeted Therapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 45: Canada Historic Review for Bone Cancer Treatment by Therapy Type - Immunotherapy & Targeted Therapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 46: Canada 16-Year Perspective for Bone Cancer Treatment by Therapy Type - Percentage Breakdown of Value Sales for Immunotherapy & Targeted Therapy and Chemotherapy for the Years 2014, 2024 & 2030
TABLE 47: Canada Recent Past, Current & Future Analysis for Bone Cancer Treatment by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 48: Canada Historic Review for Bone Cancer Treatment by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 49: Canada 16-Year Perspective for Bone Cancer Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
JAPAN
Bone Cancer Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
TABLE 50: Japan Recent Past, Current & Future Analysis for Bone Cancer Treatment by Indication - Osteosarcoma, Chondrosarcoma, Ewing Sarcoma and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 51: Japan Historic Review for Bone Cancer Treatment by Indication - Osteosarcoma, Chondrosarcoma, Ewing Sarcoma and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 52: Japan 16-Year Perspective for Bone Cancer Treatment by Indication - Percentage Breakdown of Value Sales for Osteosarcoma, Chondrosarcoma, Ewing Sarcoma and Other Indications for the Years 2014, 2024 & 2030
TABLE 53: Japan Recent Past, Current & Future Analysis for Bone Cancer Treatment by Therapy Type - Immunotherapy & Targeted Therapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 54: Japan Historic Review for Bone Cancer Treatment by Therapy Type - Immunotherapy & Targeted Therapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 55: Japan 16-Year Perspective for Bone Cancer Treatment by Therapy Type - Percentage Breakdown of Value Sales for Immunotherapy & Targeted Therapy and Chemotherapy for the Years 2014, 2024 & 2030
TABLE 56: Japan Recent Past, Current & Future Analysis for Bone Cancer Treatment by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 57: Japan Historic Review for Bone Cancer Treatment by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 58: Japan 16-Year Perspective for Bone Cancer Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
CHINA
Bone Cancer Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
TABLE 59: China Recent Past, Current & Future Analysis for Bone Cancer Treatment by Indication - Osteosarcoma, Chondrosarcoma, Ewing Sarcoma and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 60: China Historic Review for Bone Cancer Treatment by Indication - Osteosarcoma, Chondrosarcoma, Ewing Sarcoma and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 61: China 16-Year Perspective for Bone Cancer Treatment by Indication - Percentage Breakdown of Value Sales for Osteosarcoma, Chondrosarcoma, Ewing Sarcoma and Other Indications for the Years 2014, 2024 & 2030
TABLE 62: China Recent Past, Current & Future Analysis for Bone Cancer Treatment by Therapy Type - Immunotherapy & Targeted Therapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 63: China Historic Review for Bone Cancer Treatment by Therapy Type - Immunotherapy & Targeted Therapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 64: China 16-Year Perspective for Bone Cancer Treatment by Therapy Type - Percentage Breakdown of Value Sales for Immunotherapy & Targeted Therapy and Chemotherapy for the Years 2014, 2024 & 2030
TABLE 65: China Recent Past, Current & Future Analysis for Bone Cancer Treatment by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 66: China Historic Review for Bone Cancer Treatment by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 67: China 16-Year Perspective for Bone Cancer Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
EUROPE
Bone Cancer Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
TABLE 68: Europe Recent Past, Current & Future Analysis for Bone Cancer Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 69: Europe Historic Review for Bone Cancer Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 70: Europe 16-Year Perspective for Bone Cancer Treatment by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
TABLE 71: Europe Recent Past, Current & Future Analysis for Bone Cancer Treatment by Indication - Osteosarcoma, Chondrosarcoma, Ewing Sarcoma and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 72: Europe Historic Review for Bone Cancer Treatment by Indication - Osteosarcoma, Chondrosarcoma, Ewing Sarcoma and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 73: Europe 16-Year Perspective for Bone Cancer Treatment by Indication - Percentage Breakdown of Value Sales for Osteosarcoma, Chondrosarcoma, Ewing Sarcoma and Other Indications for the Years 2014, 2024 & 2030
TABLE 74: Europe Recent Past, Current & Future Analysis for Bone Cancer Treatment by Therapy Type - Immunotherapy & Targeted Therapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 75: Europe Historic Review for Bone Cancer Treatment by Therapy Type - Immunotherapy & Targeted Therapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 76: Europe 16-Year Perspective for Bone Cancer Treatment by Therapy Type - Percentage Breakdown of Value Sales for Immunotherapy & Targeted Therapy and Chemotherapy for the Years 2014, 2024 & 2030
TABLE 77: Europe Recent Past, Current & Future Analysis for Bone Cancer Treatment by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 78: Europe Historic Review for Bone Cancer Treatment by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 79: Europe 16-Year Perspective for Bone Cancer Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
FRANCE
Bone Cancer Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
TABLE 80: France Recent Past, Current & Future Analysis for Bone Cancer Treatment by Indication - Osteosarcoma, Chondrosarcoma, Ewing Sarcoma and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 81: France Historic Review for Bone Cancer Treatment by Indication - Osteosarcoma, Chondrosarcoma, Ewing Sarcoma and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 82: France 16-Year Perspective for Bone Cancer Treatment by Indication - Percentage Breakdown of Value Sales for Osteosarcoma, Chondrosarcoma, Ewing Sarcoma and Other Indications for the Years 2014, 2024 & 2030
TABLE 83: France Recent Past, Current & Future Analysis for Bone Cancer Treatment by Therapy Type - Immunotherapy & Targeted Therapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 84: France Historic Review for Bone Cancer Treatment by Therapy Type - Immunotherapy & Targeted Therapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 85: France 16-Year Perspective for Bone Cancer Treatment by Therapy Type - Percentage Breakdown of Value Sales for Immunotherapy & Targeted Therapy and Chemotherapy for the Years 2014, 2024 & 2030
TABLE 86: France Recent Past, Current & Future Analysis for Bone Cancer Treatment by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 87: France Historic Review for Bone Cancer Treatment by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 88: France 16-Year Perspective for Bone Cancer Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
GERMANY
Bone Cancer Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
TABLE 89: Germany Recent Past, Current & Future Analysis for Bone Cancer Treatment by Indication - Osteosarcoma, Chondrosarcoma, Ewing Sarcoma and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 90: Germany Historic Review for Bone Cancer Treatment by Indication - Osteosarcoma, Chondrosarcoma, Ewing Sarcoma and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 91: Germany 16-Year Perspective for Bone Cancer Treatment by Indication - Percentage Breakdown of Value Sales for Osteosarcoma, Chondrosarcoma, Ewing Sarcoma and Other Indications for the Years 2014, 2024 & 2030
TABLE 92: Germany Recent Past, Current & Future Analysis for Bone Cancer Treatment by Therapy Type - Immunotherapy & Targeted Therapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 93: Germany Historic Review for Bone Cancer Treatment by Therapy Type - Immunotherapy & Targeted Therapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 94: Germany 16-Year Perspective for Bone Cancer Treatment by Therapy Type - Percentage Breakdown of Value Sales for Immunotherapy & Targeted Therapy and Chemotherapy for the Years 2014, 2024 & 2030
TABLE 95: Germany Recent Past, Current & Future Analysis for Bone Cancer Treatment by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 96: Germany Historic Review for Bone Cancer Treatment by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 97: Germany 16-Year Perspective for Bone Cancer Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
ITALY
TABLE 98: Italy Recent Past, Current & Future Analysis for Bone Cancer Treatment by Indication - Osteosarcoma, Chondrosarcoma, Ewing Sarcoma and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 99: Italy Historic Review for Bone Cancer Treatment by Indication - Osteosarcoma, Chondrosarcoma, Ewing Sarcoma and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 100: Italy 16-Year Perspective for Bone Cancer Treatment by Indication - Percentage Breakdown of Value Sales for Osteosarcoma, Chondrosarcoma, Ewing Sarcoma and Other Indications for the Years 2014, 2024 & 2030
TABLE 101: Italy Recent Past, Current & Future Analysis for Bone Cancer Treatment by Therapy Type - Immunotherapy & Targeted Therapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 102: Italy Historic Review for Bone Cancer Treatment by Therapy Type - Immunotherapy & Targeted Therapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 103: Italy 16-Year Perspective for Bone Cancer Treatment by Therapy Type - Percentage Breakdown of Value Sales for Immunotherapy & Targeted Therapy and Chemotherapy for the Years 2014, 2024 & 2030
TABLE 104: Italy Recent Past, Current & Future Analysis for Bone Cancer Treatment by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 105: Italy Historic Review for Bone Cancer Treatment by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 106: Italy 16-Year Perspective for Bone Cancer Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
UNITED KINGDOM
Bone Cancer Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
TABLE 107: UK Recent Past, Current & Future Analysis for Bone Cancer Treatment by Indication - Osteosarcoma, Chondrosarcoma, Ewing Sarcoma and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 108: UK Historic Review for Bone Cancer Treatment by Indication - Osteosarcoma, Chondrosarcoma, Ewing Sarcoma and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 109: UK 16-Year Perspective for Bone Cancer Treatment by Indication - Percentage Breakdown of Value Sales for Osteosarcoma, Chondrosarcoma, Ewing Sarcoma and Other Indications for the Years 2014, 2024 & 2030
TABLE 110: UK Recent Past, Current & Future Analysis for Bone Cancer Treatment by Therapy Type - Immunotherapy & Targeted Therapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 111: UK Historic Review for Bone Cancer Treatment by Therapy Type - Immunotherapy & Targeted Therapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 112: UK 16-Year Perspective for Bone Cancer Treatment by Therapy Type - Percentage Breakdown of Value Sales for Immunotherapy & Targeted Therapy and Chemotherapy for the Years 2014, 2024 & 2030
TABLE 113: UK Recent Past, Current & Future Analysis for Bone Cancer Treatment by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 114: UK Historic Review for Bone Cancer Treatment by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 115: UK 16-Year Perspective for Bone Cancer Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
SPAIN
TABLE 116: Spain Recent Past, Current & Future Analysis for Bone Cancer Treatment by Indication - Osteosarcoma, Chondrosarcoma, Ewing Sarcoma and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 117: Spain Historic Review for Bone Cancer Treatment by Indication - Osteosarcoma, Chondrosarcoma, Ewing Sarcoma and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 118: Spain 16-Year Perspective for Bone Cancer Treatment by Indication - Percentage Breakdown of Value Sales for Osteosarcoma, Chondrosarcoma, Ewing Sarcoma and Other Indications for the Years 2014, 2024 & 2030
TABLE 119: Spain Recent Past, Current & Future Analysis for Bone Cancer Treatment by Therapy Type - Immunotherapy & Targeted Therapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 120: Spain Historic Review for Bone Cancer Treatment by Therapy Type - Immunotherapy & Targeted Therapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 121: Spain 16-Year Perspective for Bone Cancer Treatment by Therapy Type - Percentage Breakdown of Value Sales for Immunotherapy & Targeted Therapy and Chemotherapy for the Years 2014, 2024 & 2030
TABLE 122: Spain Recent Past, Current & Future Analysis for Bone Cancer Treatment by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 123: Spain Historic Review for Bone Cancer Treatment by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 124: Spain 16-Year Perspective for Bone Cancer Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
RUSSIA
TABLE 125: Russia Recent Past, Current & Future Analysis for Bone Cancer Treatment by Indication - Osteosarcoma, Chondrosarcoma, Ewing Sarcoma and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 126: Russia Historic Review for Bone Cancer Treatment by Indication - Osteosarcoma, Chondrosarcoma, Ewing Sarcoma and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 127: Russia 16-Year Perspective for Bone Cancer Treatment by Indication - Percentage Breakdown of Value Sales for Osteosarcoma, Chondrosarcoma, Ewing Sarcoma and Other Indications for the Years 2014, 2024 & 2030
TABLE 128: Russia Recent Past, Current & Future Analysis for Bone Cancer Treatment by Therapy Type - Immunotherapy & Targeted Therapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 129: Russia Historic Review for Bone Cancer Treatment by Therapy Type - Immunotherapy & Targeted Therapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 130: Russia 16-Year Perspective for Bone Cancer Treatment by Therapy Type - Percentage Breakdown of Value Sales for Immunotherapy & Targeted Therapy and Chemotherapy for the Years 2014, 2024 & 2030
TABLE 131: Russia Recent Past, Current & Future Analysis for Bone Cancer Treatment by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 132: Russia Historic Review for Bone Cancer Treatment by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 133: Russia 16-Year Perspective for Bone Cancer Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
REST OF EUROPE
TABLE 134: Rest of Europe Recent Past, Current & Future Analysis for Bone Cancer Treatment by Indication - Osteosarcoma, Chondrosarcoma, Ewing Sarcoma and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 135: Rest of Europe Historic Review for Bone Cancer Treatment by Indication - Osteosarcoma, Chondrosarcoma, Ewing Sarcoma and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 136: Rest of Europe 16-Year Perspective for Bone Cancer Treatment by Indication - Percentage Breakdown of Value Sales for Osteosarcoma, Chondrosarcoma, Ewing Sarcoma and Other Indications for the Years 2014, 2024 & 2030
TABLE 137: Rest of Europe Recent Past, Current & Future Analysis for Bone Cancer Treatment by Therapy Type - Immunotherapy & Targeted Therapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 138: Rest of Europe Historic Review for Bone Cancer Treatment by Therapy Type - Immunotherapy & Targeted Therapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 139: Rest of Europe 16-Year Perspective for Bone Cancer Treatment by Therapy Type - Percentage Breakdown of Value Sales for Immunotherapy & Targeted Therapy and Chemotherapy for the Years 2014, 2024 & 2030
TABLE 140: Rest of Europe Recent Past, Current & Future Analysis for Bone Cancer Treatment by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 141: Rest of Europe Historic Review for Bone Cancer Treatment by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 142: Rest of Europe 16-Year Perspective for Bone Cancer Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
ASIA-PACIFIC
Bone Cancer Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
TABLE 143: Asia-Pacific Recent Past, Current & Future Analysis for Bone Cancer Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 144: Asia-Pacific Historic Review for Bone Cancer Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 145: Asia-Pacific 16-Year Perspective for Bone Cancer Treatment by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
TABLE 146: Asia-Pacific Recent Past, Current & Future Analysis for Bone Cancer Treatment by Indication - Osteosarcoma, Chondrosarcoma, Ewing Sarcoma and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 147: Asia-Pacific Historic Review for Bone Cancer Treatment by Indication - Osteosarcoma, Chondrosarcoma, Ewing Sarcoma and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 148: Asia-Pacific 16-Year Perspective for Bone Cancer Treatment by Indication - Percentage Breakdown of Value Sales for Osteosarcoma, Chondrosarcoma, Ewing Sarcoma and Other Indications for the Years 2014, 2024 & 2030
TABLE 149: Asia-Pacific Recent Past, Current & Future Analysis for Bone Cancer Treatment by Therapy Type - Immunotherapy & Targeted Therapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 150: Asia-Pacific Historic Review for Bone Cancer Treatment by Therapy Type - Immunotherapy & Targeted Therapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 151: Asia-Pacific 16-Year Perspective for Bone Cancer Treatment by Therapy Type - Percentage Breakdown of Value Sales for Immunotherapy & Targeted Therapy and Chemotherapy for the Years 2014, 2024 & 2030
TABLE 152: Asia-Pacific Recent Past, Current & Future Analysis for Bone Cancer Treatment by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 153: Asia-Pacific Historic Review for Bone Cancer Treatment by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 154: Asia-Pacific 16-Year Perspective for Bone Cancer Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
AUSTRALIA
Bone Cancer Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
TABLE 155: Australia Recent Past, Current & Future Analysis for Bone Cancer Treatment by Indication - Osteosarcoma, Chondrosarcoma, Ewing Sarcoma and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 156: Australia Historic Review for Bone Cancer Treatment by Indication - Osteosarcoma, Chondrosarcoma, Ewing Sarcoma and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 157: Australia 16-Year Perspective for Bone Cancer Treatment by Indication - Percentage Breakdown of Value Sales for Osteosarcoma, Chondrosarcoma, Ewing Sarcoma and Other Indications for the Years 2014, 2024 & 2030
TABLE 158: Australia Recent Past, Current & Future Analysis for Bone Cancer Treatment by Therapy Type - Immunotherapy & Targeted Therapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 159: Australia Historic Review for Bone Cancer Treatment by Therapy Type - Immunotherapy & Targeted Therapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 160: Australia 16-Year Perspective for Bone Cancer Treatment by Therapy Type - Percentage Breakdown of Value Sales for Immunotherapy & Targeted Therapy and Chemotherapy for the Years 2014, 2024 & 2030
TABLE 161: Australia Recent Past, Current & Future Analysis for Bone Cancer Treatment by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 162: Australia Historic Review for Bone Cancer Treatment by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 163: Australia 16-Year Perspective for Bone Cancer Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
INDIA
Bone Cancer Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
TABLE 164: India Recent Past, Current & Future Analysis for Bone Cancer Treatment by Indication - Osteosarcoma, Chondrosarcoma, Ewing Sarcoma and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 165: India Historic Review for Bone Cancer Treatment by Indication - Osteosarcoma, Chondrosarcoma, Ewing Sarcoma and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 166: India 16-Year Perspective for Bone Cancer Treatment by Indication - Percentage Breakdown of Value Sales for Osteosarcoma, Chondrosarcoma, Ewing Sarcoma and Other Indications for the Years 2014, 2024 & 2030
TABLE 167: India Recent Past, Current & Future Analysis for Bone Cancer Treatment by Therapy Type - Immunotherapy & Targeted Therapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 168: India Historic Review for Bone Cancer Treatment by Therapy Type - Immunotherapy & Targeted Therapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 169: India 16-Year Perspective for Bone Cancer Treatment by Therapy Type - Percentage Breakdown of Value Sales for Immunotherapy & Targeted Therapy and Chemotherapy for the Years 2014, 2024 & 2030
TABLE 170: India Recent Past, Current & Future Analysis for Bone Cancer Treatment by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 171: India Historic Review for Bone Cancer Treatment by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 172: India 16-Year Perspective for Bone Cancer Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
SOUTH KOREA
TABLE 173: South Korea Recent Past, Current & Future Analysis for Bone Cancer Treatment by Indication - Osteosarcoma, Chondrosarcoma, Ewing Sarcoma and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 174: South Korea Historic Review for Bone Cancer Treatment by Indication - Osteosarcoma, Chondrosarcoma, Ewing Sarcoma and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 175: South Korea 16-Year Perspective for Bone Cancer Treatment by Indication - Percentage Breakdown of Value Sales for Osteosarcoma, Chondrosarcoma, Ewing Sarcoma and Other Indications for the Years 2014, 2024 & 2030
TABLE 176: South Korea Recent Past, Current & Future Analysis for Bone Cancer Treatment by Therapy Type - Immunotherapy & Targeted Therapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 177: South Korea Historic Review for Bone Cancer Treatment by Therapy Type - Immunotherapy & Targeted Therapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 178: South Korea 16-Year Perspective for Bone Cancer Treatment by Therapy Type - Percentage Breakdown of Value Sales for Immunotherapy & Targeted Therapy and Chemotherapy for the Years 2014, 2024 & 2030
TABLE 179: South Korea Recent Past, Current & Future Analysis for Bone Cancer Treatment by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 180: South Korea Historic Review for Bone Cancer Treatment by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 181: South Korea 16-Year Perspective for Bone Cancer Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
REST OF ASIA-PACIFIC
TABLE 182: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Bone Cancer Treatment by Indication - Osteosarcoma, Chondrosarcoma, Ewing Sarcoma and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 183: Rest of Asia-Pacific Historic Review for Bone Cancer Treatment by Indication - Osteosarcoma, Chondrosarcoma, Ewing Sarcoma and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 184: Rest of Asia-Pacific 16-Year Perspective for Bone Cancer Treatment by Indication - Percentage Breakdown of Value Sales for Osteosarcoma, Chondrosarcoma, Ewing Sarcoma and Other Indications for the Years 2014, 2024 & 2030
TABLE 185: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Bone Cancer Treatment by Therapy Type - Immunotherapy & Targeted Therapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 186: Rest of Asia-Pacific Historic Review for Bone Cancer Treatment by Therapy Type - Immunotherapy & Targeted Therapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 187: Rest of Asia-Pacific 16-Year Perspective for Bone Cancer Treatment by Therapy Type - Percentage Breakdown of Value Sales for Immunotherapy & Targeted Therapy and Chemotherapy for the Years 2014, 2024 & 2030
TABLE 188: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Bone Cancer Treatment by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 189: Rest of Asia-Pacific Historic Review for Bone Cancer Treatment by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 190: Rest of Asia-Pacific 16-Year Perspective for Bone Cancer Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
LATIN AMERICA
Bone Cancer Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
TABLE 191: Latin America Recent Past, Current & Future Analysis for Bone Cancer Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 192: Latin America Historic Review for Bone Cancer Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 193: Latin America 16-Year Perspective for Bone Cancer Treatment by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
TABLE 194: Latin America Recent Past, Current & Future Analysis for Bone Cancer Treatment by Indication - Osteosarcoma, Chondrosarcoma, Ewing Sarcoma and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 195: Latin America Historic Review for Bone Cancer Treatment by Indication - Osteosarcoma, Chondrosarcoma, Ewing Sarcoma and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 196: Latin America 16-Year Perspective for Bone Cancer Treatment by Indication - Percentage Breakdown of Value Sales for Osteosarcoma, Chondrosarcoma, Ewing Sarcoma and Other Indications for the Years 2014, 2024 & 2030
TABLE 197: Latin America Recent Past, Current & Future Analysis for Bone Cancer Treatment by Therapy Type - Immunotherapy & Targeted Therapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 198: Latin America Historic Review for Bone Cancer Treatment by Therapy Type - Immunotherapy & Targeted Therapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 199: Latin America 16-Year Perspective for Bone Cancer Treatment by Therapy Type - Percentage Breakdown of Value Sales for Immunotherapy & Targeted Therapy and Chemotherapy for the Years 2014, 2024 & 2030
TABLE 200: Latin America Recent Past, Current & Future Analysis for Bone Cancer Treatment by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 201: Latin America Historic Review for Bone Cancer Treatment by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 202: Latin America 16-Year Perspective for Bone Cancer Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
ARGENTINA
TABLE 203: Argentina Recent Past, Current & Future Analysis for Bone Cancer Treatment by Indication - Osteosarcoma, Chondrosarcoma, Ewing Sarcoma and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 204: Argentina Historic Review for Bone Cancer Treatment by Indication - Osteosarcoma, Chondrosarcoma, Ewing Sarcoma and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 205: Argentina 16-Year Perspective for Bone Cancer Treatment by Indication - Percentage Breakdown of Value Sales for Osteosarcoma, Chondrosarcoma, Ewing Sarcoma and Other Indications for the Years 2014, 2024 & 2030
TABLE 206: Argentina Recent Past, Current & Future Analysis for Bone Cancer Treatment by Therapy Type - Immunotherapy & Targeted Therapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 207: Argentina Historic Review for Bone Cancer Treatment by Therapy Type - Immunotherapy & Targeted Therapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 208: Argentina 16-Year Perspective for Bone Cancer Treatment by Therapy Type - Percentage Breakdown of Value Sales for Immunotherapy & Targeted Therapy and Chemotherapy for the Years 2014, 2024 & 2030
TABLE 209: Argentina Recent Past, Current & Future Analysis for Bone Cancer Treatment by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 210: Argentina Historic Review for Bone Cancer Treatment by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 211: Argentina 16-Year Perspective for Bone Cancer Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
BRAZIL
TABLE 212: Brazil Recent Past, Current & Future Analysis for Bone Cancer Treatment by Indication - Osteosarcoma, Chondrosarcoma, Ewing Sarcoma and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 213: Brazil Historic Review for Bone Cancer Treatment by Indication - Osteosarcoma, Chondrosarcoma, Ewing Sarcoma and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 214: Brazil 16-Year Perspective for Bone Cancer Treatment by Indication - Percentage Breakdown of Value Sales for Osteosarcoma, Chondrosarcoma, Ewing Sarcoma and Other Indications for the Years 2014, 2024 & 2030
TABLE 215: Brazil Recent Past, Current & Future Analysis for Bone Cancer Treatment by Therapy Type - Immunotherapy & Targeted Therapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 216: Brazil Historic Review for Bone Cancer Treatment by Therapy Type - Immunotherapy & Targeted Therapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 217: Brazil 16-Year Perspective for Bone Cancer Treatment by Therapy Type - Percentage Breakdown of Value Sales for Immunotherapy & Targeted Therapy and Chemotherapy for the Years 2014, 2024 & 2030
TABLE 218: Brazil Recent Past, Current & Future Analysis for Bone Cancer Treatment by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 219: Brazil Historic Review for Bone Cancer Treatment by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 220: Brazil 16-Year Perspective for Bone Cancer Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
MEXICO
TABLE 221: Mexico Recent Past, Current & Future Analysis for Bone Cancer Treatment by Indication - Osteosarcoma, Chondrosarcoma, Ewing Sarcoma and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 222: Mexico Historic Review for Bone Cancer Treatment by Indication - Osteosarcoma, Chondrosarcoma, Ewing Sarcoma and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 223: Mexico 16-Year Perspective for Bone Cancer Treatment by Indication - Percentage Breakdown of Value Sales for Osteosarcoma, Chondrosarcoma, Ewing Sarcoma and Other Indications for the Years 2014, 2024 & 2030
TABLE 224: Mexico Recent Past, Current & Future Analysis for Bone Cancer Treatment by Therapy Type - Immunotherapy & Targeted Therapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 225: Mexico Historic Review for Bone Cancer Treatment by Therapy Type - Immunotherapy & Targeted Therapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 226: Mexico 16-Year Perspective for Bone Cancer Treatment by Therapy Type - Percentage Breakdown of Value Sales for Immunotherapy & Targeted Therapy and Chemotherapy for the Years 2014, 2024 & 2030
TABLE 227: Mexico Recent Past, Current & Future Analysis for Bone Cancer Treatment by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 228: Mexico Historic Review for Bone Cancer Treatment by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 229: Mexico 16-Year Perspective for Bone Cancer Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
REST OF LATIN AMERICA
TABLE 230: Rest of Latin America Recent Past, Current & Future Analysis for Bone Cancer Treatment by Indication - Osteosarcoma, Chondrosarcoma, Ewing Sarcoma and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 231: Rest of Latin America Historic Review for Bone Cancer Treatment by Indication - Osteosarcoma, Chondrosarcoma, Ewing Sarcoma and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 232: Rest of Latin America 16-Year Perspective for Bone Cancer Treatment by Indication - Percentage Breakdown of Value Sales for Osteosarcoma, Chondrosarcoma, Ewing Sarcoma and Other Indications for the Years 2014, 2024 & 2030
TABLE 233: Rest of Latin America Recent Past, Current & Future Analysis for Bone Cancer Treatment by Therapy Type - Immunotherapy & Targeted Therapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 234: Rest of Latin America Historic Review for Bone Cancer Treatment by Therapy Type - Immunotherapy & Targeted Therapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 235: Rest of Latin America 16-Year Perspective for Bone Cancer Treatment by Therapy Type - Percentage Breakdown of Value Sales for Immunotherapy & Targeted Therapy and Chemotherapy for the Years 2014, 2024 & 2030
TABLE 236: Rest of Latin America Recent Past, Current & Future Analysis for Bone Cancer Treatment by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 237: Rest of Latin America Historic Review for Bone Cancer Treatment by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 238: Rest of Latin America 16-Year Perspective for Bone Cancer Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
MIDDLE EAST
Bone Cancer Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
TABLE 239: Middle East Recent Past, Current & Future Analysis for Bone Cancer Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 240: Middle East Historic Review for Bone Cancer Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 241: Middle East 16-Year Perspective for Bone Cancer Treatment by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
TABLE 242: Middle East Recent Past, Current & Future Analysis for Bone Cancer Treatment by Indication - Osteosarcoma, Chondrosarcoma, Ewing Sarcoma and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 243: Middle East Historic Review for Bone Cancer Treatment by Indication - Osteosarcoma, Chondrosarcoma, Ewing Sarcoma and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 244: Middle East 16-Year Perspective for Bone Cancer Treatment by Indication - Percentage Breakdown of Value Sales for Osteosarcoma, Chondrosarcoma, Ewing Sarcoma and Other Indications for the Years 2014, 2024 & 2030
TABLE 245: Middle East Recent Past, Current & Future Analysis for Bone Cancer Treatment by Therapy Type - Immunotherapy & Targeted Therapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 246: Middle East Historic Review for Bone Cancer Treatment by Therapy Type - Immunotherapy & Targeted Therapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 247: Middle East 16-Year Perspective for Bone Cancer Treatment by Therapy Type - Percentage Breakdown of Value Sales for Immunotherapy & Targeted Therapy and Chemotherapy for the Years 2014, 2024 & 2030
TABLE 248: Middle East Recent Past, Current & Future Analysis for Bone Cancer Treatment by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 249: Middle East Historic Review for Bone Cancer Treatment by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 250: Middle East 16-Year Perspective for Bone Cancer Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
IRAN
TABLE 251: Iran Recent Past, Current & Future Analysis for Bone Cancer Treatment by Indication - Osteosarcoma, Chondrosarcoma, Ewing Sarcoma and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 252: Iran Historic Review for Bone Cancer Treatment by Indication - Osteosarcoma, Chondrosarcoma, Ewing Sarcoma and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 253: Iran 16-Year Perspective for Bone Cancer Treatment by Indication - Percentage Breakdown of Value Sales for Osteosarcoma, Chondrosarcoma, Ewing Sarcoma and Other Indications for the Years 2014, 2024 & 2030
TABLE 254: Iran Recent Past, Current & Future Analysis for Bone Cancer Treatment by Therapy Type - Immunotherapy & Targeted Therapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 255: Iran Historic Review for Bone Cancer Treatment by Therapy Type - Immunotherapy & Targeted Therapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 256: Iran 16-Year Perspective for Bone Cancer Treatment by Therapy Type - Percentage Breakdown of Value Sales for Immunotherapy & Targeted Therapy and Chemotherapy for the Years 2014, 2024 & 2030
TABLE 257: Iran Recent Past, Current & Future Analysis for Bone Cancer Treatment by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 258: Iran Historic Review for Bone Cancer Treatment by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 259: Iran 16-Year Perspective for Bone Cancer Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
ISRAEL
TABLE 260: Israel Recent Past, Current & Future Analysis for Bone Cancer Treatment by Indication - Osteosarcoma, Chondrosarcoma, Ewing Sarcoma and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 261: Israel Historic Review for Bone Cancer Treatment by Indication - Osteosarcoma, Chondrosarcoma, Ewing Sarcoma and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 262: Israel 16-Year Perspective for Bone Cancer Treatment by Indication - Percentage Breakdown of Value Sales for Osteosarcoma, Chondrosarcoma, Ewing Sarcoma and Other Indications for the Years 2014, 2024 & 2030
TABLE 263: Israel Recent Past, Current & Future Analysis for Bone Cancer Treatment by Therapy Type - Immunotherapy & Targeted Therapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 264: Israel Historic Review for Bone Cancer Treatment by Therapy Type - Immunotherapy & Targeted Therapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 265: Israel 16-Year Perspective for Bone Cancer Treatment by Therapy Type - Percentage Breakdown of Value Sales for Immunotherapy & Targeted Therapy and Chemotherapy for the Years 2014, 2024 & 2030
TABLE 266: Israel Recent Past, Current & Future Analysis for Bone Cancer Treatment by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 267: Israel Historic Review for Bone Cancer Treatment by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 268: Israel 16-Year Perspective for Bone Cancer Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
SAUDI ARABIA
TABLE 269: Saudi Arabia Recent Past, Current & Future Analysis for Bone Cancer Treatment by Indication - Osteosarcoma, Chondrosarcoma, Ewing Sarcoma and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 270: Saudi Arabia Historic Review for Bone Cancer Treatment by Indication - Osteosarcoma, Chondrosarcoma, Ewing Sarcoma and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 271: Saudi Arabia 16-Year Perspective for Bone Cancer Treatment by Indication - Percentage Breakdown of Value Sales for Osteosarcoma, Chondrosarcoma, Ewing Sarcoma and Other Indications for the Years 2014, 2024 & 2030
TABLE 272: Saudi Arabia Recent Past, Current & Future Analysis for Bone Cancer Treatment by Therapy Type - Immunotherapy & Targeted Therapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 273: Saudi Arabia Historic Review for Bone Cancer Treatment by Therapy Type - Immunotherapy & Targeted Therapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 274: Saudi Arabia 16-Year Perspective for Bone Cancer Treatment by Therapy Type - Percentage Breakdown of Value Sales for Immunotherapy & Targeted Therapy and Chemotherapy for the Years 2014, 2024 & 2030
TABLE 275: Saudi Arabia Recent Past, Current & Future Analysis for Bone Cancer Treatment by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 276: Saudi Arabia Historic Review for Bone Cancer Treatment by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 277: Saudi Arabia 16-Year Perspective for Bone Cancer Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
UNITED ARAB EMIRATES
TABLE 278: UAE Recent Past, Current & Future Analysis for Bone Cancer Treatment by Indication - Osteosarcoma, Chondrosarcoma, Ewing Sarcoma and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 279: UAE Historic Review for Bone Cancer Treatment by Indication - Osteosarcoma, Chondrosarcoma, Ewing Sarcoma and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 280: UAE 16-Year Perspective for Bone Cancer Treatment by Indication - Percentage Breakdown of Value Sales for Osteosarcoma, Chondrosarcoma, Ewing Sarcoma and Other Indications for the Years 2014, 2024 & 2030
TABLE 281: UAE Recent Past, Current & Future Analysis for Bone Cancer Treatment by Therapy Type - Immunotherapy & Targeted Therapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 282: UAE Historic Review for Bone Cancer Treatment by Therapy Type - Immunotherapy & Targeted Therapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 283: UAE 16-Year Perspective for Bone Cancer Treatment by Therapy Type - Percentage Breakdown of Value Sales for Immunotherapy & Targeted Therapy and Chemotherapy for the Years 2014, 2024 & 2030
TABLE 284: UAE Recent Past, Current & Future Analysis for Bone Cancer Treatment by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 285: UAE Historic Review for Bone Cancer Treatment by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 286: UAE 16-Year Perspective for Bone Cancer Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
REST OF MIDDLE EAST
TABLE 287: Rest of Middle East Recent Past, Current & Future Analysis for Bone Cancer Treatment by Indication - Osteosarcoma, Chondrosarcoma, Ewing Sarcoma and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 288: Rest of Middle East Historic Review for Bone Cancer Treatment by Indication - Osteosarcoma, Chondrosarcoma, Ewing Sarcoma and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 289: Rest of Middle East 16-Year Perspective for Bone Cancer Treatment by Indication - Percentage Breakdown of Value Sales for Osteosarcoma, Chondrosarcoma, Ewing Sarcoma and Other Indications for the Years 2014, 2024 & 2030
TABLE 290: Rest of Middle East Recent Past, Current & Future Analysis for Bone Cancer Treatment by Therapy Type - Immunotherapy & Targeted Therapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 291: Rest of Middle East Historic Review for Bone Cancer Treatment by Therapy Type - Immunotherapy & Targeted Therapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 292: Rest of Middle East 16-Year Perspective for Bone Cancer Treatment by Therapy Type - Percentage Breakdown of Value Sales for Immunotherapy & Targeted Therapy and Chemotherapy for the Years 2014, 2024 & 2030
TABLE 293: Rest of Middle East Recent Past, Current & Future Analysis for Bone Cancer Treatment by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 294: Rest of Middle East Historic Review for Bone Cancer Treatment by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 295: Rest of Middle East 16-Year Perspective for Bone Cancer Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
AFRICA
Bone Cancer Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
TABLE 296: Africa Recent Past, Current & Future Analysis for Bone Cancer Treatment by Indication - Osteosarcoma, Chondrosarcoma, Ewing Sarcoma and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 297: Africa Historic Review for Bone Cancer Treatment by Indication - Osteosarcoma, Chondrosarcoma, Ewing Sarcoma and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 298: Africa 16-Year Perspective for Bone Cancer Treatment by Indication - Percentage Breakdown of Value Sales for Osteosarcoma, Chondrosarcoma, Ewing Sarcoma and Other Indications for the Years 2014, 2024 & 2030
TABLE 299: Africa Recent Past, Current & Future Analysis for Bone Cancer Treatment by Therapy Type - Immunotherapy & Targeted Therapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 300: Africa Historic Review for Bone Cancer Treatment by Therapy Type - Immunotherapy & Targeted Therapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 301: Africa 16-Year Perspective for Bone Cancer Treatment by Therapy Type - Percentage Breakdown of Value Sales for Immunotherapy & Targeted Therapy and Chemotherapy for the Years 2014, 2024 & 2030
TABLE 302: Africa Recent Past, Current & Future Analysis for Bone Cancer Treatment by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 303: Africa Historic Review for Bone Cancer Treatment by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 304: Africa 16-Year Perspective for Bone Cancer Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030